New class of kidney cancer drugs potentially more effective than sunitinib

A recent pre-clinical study published in the journal Nature shows that a new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer. Hypoxia-inducible factors (HIFs), such as HIF-2, allow the body’s cells to adjust to low-oxygen environments. HIFs are part of a […]

read more

Biomarkers predict response to TKI therapy for kidney cancer patients

A recent study published last month provides evidence that the presence of small pieces of genetic material, called microRNAs (miRNAs), in the cancer cells can predict response to treatment with tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC). The miRNAs define patients refractory to TKI therapy who have a poor prognosis. […]

read more

Researchers discover a mechanism that reverses TKI drug resistance

Researchers from the Breast Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) have discovered a resistance mechanism to antiangiogenic drugs, a class of drugs commonly used to treat cancer. They published their findings in the journal Cell Reports recently, where they describe the resistance mechanism to these compounds and, more importantly, a way to […]

read more

First patient dosed in pivotal phase 3 clinical trial of tivozanib in renal cell carcinoma

AVEO Oncology has enrolled and dosed the first patient in a pivotal phase 3 clinical trial, TIVO-3, to compare tivozanib with sorafenib in people with advanced renal cell carcinoma (RCC) that has stopped responding to treatment. Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). TIVO-3 is a randomised, controlled, […]

read more

FDA approves lenvatinib/everolimus combination for kidney cancer

The FDA has approved the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogeneic therapy, based on survival and response data from a phase II study. In the trial, known as Study 205, the combination of lenvatinib and everolimus reduced the risk of […]

read more

Common supplement boosts kidney cancer therapy

A recent study published in the journal Molecular Cancer Therapeutics by researchers at University College Davis Comprehensive Cancer Center in the US, shows that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces the invasiveness of renal cell carcinomas (RCC), growth rate, and blood vessel growth when combined with […]

read more

Novel therapies shaking up the treatment of kidney cancer

The following round table discussion between a panel of doctors (oncologists) discusses the recent advances in how renal cell carcinoma (RCC) is treated. Although treatment options for RCC have improved dramatically over the past decade, oncologists often face difficult decisions in selecting the right course of treatment for the individual patient, such as; which drug(s) […]

read more
Showing 131 to 137 of 137 results
  TOP